Stock Events

Stock Events

Bitwise MARA Option Income Strategy 

$12.78
961
+$0.51+4.16% Tuesday 19:53

Statistics

Day High
12.81
Day Low
12.3
52W High
60.73
52W Low
11.99
Volume
9,851
Avg. Volume
5,816
Mkt Cap
758.45M
P/E Ratio
105.33
Dividend Yield
239.64%
Dividend
30.63

Upcoming

27
APR
Dividend Ex
Estimated
 
1
MAY
Dividend Payment
Estimated
 
27
MAY
Dividend Ex
Estimated
 
29
JUN
Dividend Ex
Estimated
 
1
JUL
Dividend Payment
Estimated
 

Dividends

239.64%Dividend Yield
May 26
$2.55
Mar 26
$0.25
Mar 26
$0.31
Jan 26
$0.21
Dec 25
$1.42
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
-13.1%

Earnings

20MayExpected
Q4 2022
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.57
-0.45
-0.32
-0.2
Expected EPS
-0.461243
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-178.05MNet Income

Analyst Ratings

$50.50Average Price Target
The highest estimate is 56.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMRA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a global healthcare company that operates in the same oncology space, competing directly with Enliven Therapeutics' cancer-focused therapies.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines in areas including oncology, directly competing with Enliven Therapeutics.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a broad range of oncology products that compete in the same market as Enliven Therapeutics' cancer treatments.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC has a strong focus on oncology, with a portfolio that competes with Enliven Therapeutics in developing cancer therapies.
Novartis
NVS
Mkt Cap237.61B
Novartis AG focuses on innovative healthcare solutions, including oncology, where it competes with Enliven Therapeutics in the cancer treatment space.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG, through its pharmaceuticals division, is a leader in oncology, directly competing with Enliven Therapeutics in cancer drug development.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. is known for its strong presence in the oncology market, offering competitive therapies to those developed by Enliven Therapeutics.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. competes in the biopharmaceutical space, focusing on innovative therapies including oncology, which puts it in direct competition with Enliven Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is involved in the discovery and development of pharmaceutical products for the treatment of cancer, among other diseases, competing with Enliven Therapeutics.

About

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Show more...
CEO
Dr. Rahul D. Ballal Ph.D.
Employees
41
Country
US
ISIN
US0917487078

Listings

ARCX
US
IMRA
BOATS
BOATS
ELVN.BOATS
XNAS
US
ELVN

0 Comments

Share your thoughts

FAQ

What is Bitwise MARA Option Income Strategy stock price today?▼
The current price of IMRA is $12.78 USD — it has increased by +4.16% in the past 24 hours. Watch Bitwise MARA Option Income Strategy stock price performance more closely on the chart.
What is Bitwise MARA Option Income Strategy stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Bitwise MARA Option Income Strategy stocks are traded under the ticker IMRA.
What is Bitwise MARA Option Income Strategy market cap?▼
Today Bitwise MARA Option Income Strategy has the market capitalization of 758.45M
When is the next Bitwise MARA Option Income Strategy earnings date?▼
Bitwise MARA Option Income Strategy is going to release the next earnings report on May 20, 2026.
What were Bitwise MARA Option Income Strategy earnings last quarter?▼
IMRA earnings for the last quarter are -0.48 USD per share, whereas the estimation was -0.39 USD resulting in a -24.68% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bitwise MARA Option Income Strategy revenue for the last year?▼
Bitwise MARA Option Income Strategy revenue for the last year amounts to 0 USD.
What is Bitwise MARA Option Income Strategy net income for the last year?▼
IMRA net income for the last year is -178.05M USD.
Does Bitwise MARA Option Income Strategy pay dividends?▼
Yes, IMRA dividends are paid monthly. The last dividend per share was 0.25 USD. As of today, Dividend Yield (FWD)% is 239.64%.
How many employees does Bitwise MARA Option Income Strategy have?▼
As of April 01, 2026, the company has 41 employees.
In which sector is Bitwise MARA Option Income Strategy located?▼
Bitwise MARA Option Income Strategy operates in the Health Care sector.
When did Bitwise MARA Option Income Strategy complete a stock split?▼
The last stock split for Bitwise MARA Option Income Strategy was on February 24, 2023 with a ratio of 1:4.
Where is Bitwise MARA Option Income Strategy headquartered?▼
Bitwise MARA Option Income Strategy is headquartered in Boston, US.